Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Stock Report

Mkt Cap: US$959.5m

We’ve recently updated our valuation analysis.

Collegium Pharmaceutical Valuation

Is COLL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLL?

Other financial metrics that can be useful for relative valuation.

COLL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA9.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does COLL's PS Ratio compare to its peers?

The above table shows the PS ratio for COLL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.9x
INVA Innoviva
2.3x-12.4%US$867.4m
TARO Taro Pharmaceutical Industries
2xn/aUS$1.2b
ANIP ANI Pharmaceuticals
2.5x9.6%US$709.7m
PAHC Phibro Animal Health
0.6x3.6%US$613.6m
COLL Collegium Pharmaceutical
2.7x2.3%US$959.5m

Price-To-Sales vs Peers: COLL is expensive based on its Price-To-Sales Ratio (2.7x) compared to the peer average (1.9x).


Price to Earnings Ratio vs Industry

How does COLL's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a

Price-To-Sales vs Industry: COLL is good value based on its Price-To-Sales Ratio (2.7x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is COLL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: COLL is good value based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).


Share Price vs Fair Value

What is the Fair Price of COLL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COLL ($28.58) is trading below our estimate of fair value ($130.5)

Significantly Below Fair Value: COLL is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$28.58
US$32.25
+12.8%
11.5%US$35.00US$26.00n/a4
Jan ’24US$23.20
US$30.25
+30.4%
14.1%US$35.00US$26.00n/a4
Dec ’23US$22.88
US$30.25
+32.2%
14.1%US$35.00US$26.00n/a4
Nov ’23US$18.55
US$31.75
+71.2%
15.2%US$37.00US$26.00n/a4
Oct ’23US$16.02
US$31.75
+98.2%
15.2%US$37.00US$26.00n/a4
Sep ’23US$17.70
US$31.75
+79.4%
15.2%US$37.00US$26.00n/a4
Aug ’23US$17.00
US$31.20
+83.5%
14.2%US$37.00US$26.00n/a5
Jul ’23US$18.16
US$28.86
+58.9%
32.8%US$37.00US$8.00n/a7
Jun ’23US$15.48
US$28.86
+86.4%
32.8%US$37.00US$8.00n/a7
May ’23US$16.10
US$28.14
+74.8%
33.3%US$40.00US$8.00n/a7
Apr ’23US$19.73
US$28.14
+42.6%
33.9%US$42.00US$8.00n/a7
Mar ’23US$18.51
US$28.14
+52.0%
33.9%US$42.00US$8.00n/a7
Feb ’23US$18.04
US$25.50
+41.4%
32.5%US$36.00US$8.00n/a8
Jan ’23US$18.68
US$25.63
+37.2%
32.4%US$36.00US$8.00US$23.208
Dec ’22US$17.50
US$25.63
+46.4%
32.4%US$36.00US$8.00US$22.888
Nov ’22US$20.62
US$26.88
+30.3%
30.3%US$36.00US$8.00US$18.558
Oct ’22US$19.96
US$27.00
+35.3%
30.3%US$36.00US$8.00US$16.028
Sep ’22US$20.14
US$27.00
+34.1%
30.3%US$36.00US$8.00US$17.708
Aug ’22US$24.89
US$29.63
+19.0%
29.7%US$40.00US$8.00US$17.008
Jul ’22US$23.99
US$29.63
+23.5%
29.7%US$40.00US$8.00US$18.168
Jun ’22US$22.90
US$29.63
+29.4%
29.7%US$40.00US$8.00US$15.488
May ’22US$22.30
US$29.75
+33.4%
30.0%US$41.00US$8.00US$16.108
Apr ’22US$23.38
US$29.63
+26.7%
30.0%US$41.00US$8.00US$19.738
Mar ’22US$22.93
US$29.63
+29.2%
30.0%US$41.00US$8.00US$18.518
Feb ’22US$23.04
US$28.25
+22.6%
30.6%US$38.00US$8.00US$18.048
Jan ’22US$20.03
US$28.13
+40.4%
31.0%US$38.00US$8.00US$18.688

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies